Lansoprazole Capsule, Delayed Release
Product Images NDC 68071-3572

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Lansoprazole (NDC 68071-3572). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3572 4)

Pdp (68071 3572 4)
Label for Lansoprazole 30 mg delayed-release capsules by NuCare Pharmaceuticals, Inc. The label indicates 14 capsules per package with an oblong opaque white body and light blue cap, marked with 'A263' and '30mg'. It includes manufacturer and packaging details, a barcode, and storage instructions at controlled temperatures (68-77°F).*
FDA Label Image

Figure-1.jpg (Figure 1)

Figure-1.jpg (Figure 1)
A line graph showing mean severity of day heartburn over time from the start of treatment. It compares placebo, Lansoprazole 15 mg QD, and Lansoprazole 30 mg QD groups in evaluable patients, with severity scores from 0 (none) to 3 (severe) on the y-axis and days from start of treatment on the x-axis.*
FDA Label Image

Figure-2.jpg (Figure 2)

Figure-2.jpg (Figure 2)
A line graph showing the mean severity of night heartburn by study day for evaluable patients. The graph compares placebo, Lansoprazole 15 mg QD, and Lansoprazole 30 mg QD over approximately 60 days from treatment start, with severity rated from 0 (none) to 3 (severe). The graph illustrates decreasing heartburn severity over time for both Lansoprazole doses compared to placebo.*
FDA Label Image

Formula-structure.jpg (Image 01)

Formula-structure.jpg (Image 01)
Chemical structure of Lansoprazole, showing its molecular framework with heterocyclic rings and functional groups including a sulfoxide and trifluoromethoxy substituent.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.